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a b s t r a c t
High-risk types of human papillomavirus (HPV) cause nearly all cases of cervical cancer. The E6
oncoprotein is produced as a full-length variant (E6) as well as several shorter isoforms (E6n). E6n
inhibits certain oncogenic activities of E6, suggesting that it might play an anti-oncogenic role in vivo.
To test this, we created E6n-expressing SiHa (HPVþ) and C33A (HPV) cells, then examined the ability of
both the parental and E6n-expressing cells to form tumors in nude mice. We found that over-expression
of E6n indeed decreased the growth of tumors derived from both SiHa and C33A cells, with the reduction
greatest in tumors derived from E6n-expressing SiHa cells. These ﬁndings point to multiple anti-
oncogenic characteristics of E6n, some of which likely involve down-regulation of the full-length isoform,
and others that are independent of HPV. These data represent the ﬁrst demonstration of biologically-
relevant E6n activities distinct from those of the full-length isoform in vivo.
& 2013 Elsevier Inc. All rights reserved.
Introduction
High-risk types of the human papillomavirus (HPV) are the
causative agents of nearly all cases of cervical cancer, as well as a
signiﬁcant number of head, neck, penile, vulvar, and anal cancers.
Like many other viruses with small genomes, HPV (8 kb) utilizes
numerous mechanisms to increase the capacity of its genome to
encode the proteins necessary for successful completion of its
infectious life cycle. Alternative splicing of viral mRNA is one
common mechanism used by many viruses, including HPV, to
produce multiple proteins from a limited genetic sequence. The
early HPV genes (E1, E2, E4, E5, E6 and E7), and in particular, E1,
E2, E6 and E7, have been studied intensively over the last 2 decades
(Bodily and Laimins, 2011; Ghittoni et al., 2010; Graham, 2010;
McLaughlin-Drubin and Munger, 2009; Moody and Laimins, 2010;
Munger and Howley, 2002; Pim and Banks, 2010). Their activities
and roles in the virus life cycle and during cellular transformation
have been well established, with the E6 and E7 oncogenes from
high -risk types implicated as the major transforming agents.
However, the functions of their alternatively spliced products have
not yet been closely examined, even though increasing evidence
suggests that these proteins may play important roles in the viral
life cycle as well as contribute to carcinogenesis. For example, the
splicing product E1\E4 has been linked to the productive life cycle.
This function is associated with keratin networks, although the
exact mechanism has not yet been elucidated (Doorbar et al.,
1991). Additionally, over-expression of HPV-11 and HPV-16 E1\E4
has been shown to induce G2 arrest (Davy et al., 2002). Another
example of an HPV splice product with a biologically important
role is the spliced E8\E2C fusion protein, which functions as a
negative regulator of viral transcription and replication for HPV 31
(Stubenrauch et al., 2000, 2001).
The E6 and E7 oncogenes of high-risk HPVs are predominantly
transcribed as an early transcript from the early promoter that
produces bicistronic E6/E7 pre-mRNA. If the introns within this
E6/E7 transcript remain unspliced, the resulting mRNA expresses
oncogenic full -length E6. If, however, these introns are spliced
out, several splice variants are possible. High-risk HPVs possess
one 50 donor splice site within the E6 coding region and multiple
acceptor splice sites localized within E6 as well as in other genes
(Zheng and Baker, 2006). The E6nI and E6nII splice variants are
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produced when the acceptor sites are localized within the E6
sequence, and their protein products are quite similar as they
differ only in the last 7 aa (Fig. 1A). The ability to produce splice
variants of E6 appears to be a characteristic of high-risk types of
HPVs, as HPV 16, HPV 18, HPV 31, HPV 33, and HPV 45 do produce
these variants (Sotlar et al., 2004), while low-risk types such as
HPV 6b and HPV 11 do not (Filippova et al., 2007; Pim et al., 2009).
This difference in the presence of E6 splice variants between low-
and high-risk HPV types may suggest that E6 splicing plays a role
in viral oncogenesis (Zheng, 2010). An alternative suggestion is
that this alternate splicing is somehow required for successful
completion of the high-risk (but not the low-risk) life cycle.
One initial explanation for these splice variants was that such
splicing, particularly splicing of intron 1 resulting in the E6nI
transcript, beneﬁted E7 expression (Tang et al., 2006). Investiga-
tors showed that when protein translation occurs on E6E7 mRNA,
the space between termination of E6 translation and the initiation
of E7 is not sufﬁcient for effective translation of E7 (Zheng et al.,
2004). However, there is enough space on the spliced E6nI-E7
mRNA for termination of E6nI translation and re-initiation of E7
translation (Zheng et al., 2004), leading to the suggestion that the
purpose of E6 splicing was simply to promote E7 expression.
Interestingly, although the presence of transcripts coding for E6
splice variants has been acknowledged for several years the
activity and existence of the E6n protein has remained under
question. The recent availability of antibodies with improved
sensitivity and speciﬁcity for E6 and E6n has now allowed us to
demonstrate the presence of E6n at the protein level in cervical
cancer cell lines, and to observe differences in the expression
levels of both E6 and E6n between the CaSki and SiHa cervical
carcinoma cell lines (Filippova et al., 2009). We found not only that
E6n is indeed produced at detectable levels, but that it is biologi-
cally active as well. For example, we demonstrated that the over-
expression of E6n in SiHa cells sensitizes these cells to apoptosis
induced through the TNF and Fas pathways (Filippova et al., 2009),
indicating a possible pro-apoptotic role for this protein. Additional
functions of E6n from HPV18 have been demonstrated by the
Banks group (Pim et al., 1997), showing that HPV 18 E6n can
suppress the growth of transformed cellsand decrease the ability
of the full-length isoform to degrade p53.
This data, suggesting that E6n possesses anti-oncogenic activ-
ities, led to the intriguing proposal that the truncated isoform
might play a distinct role in carcinogenesis, possibly by opposing
activities of the full-length isoform. Each of the studies noted
above was carried out in the context of cell lines; thus, to test the
prospect that E6n might act as an anti-oncogene in vivo, we
examined the inﬂuence of E6n on tumor formation in a cervical
cancer xenograft model. To discriminate between activities that
require the presence of the full-length isoform and activities that
are independent of E6, we asked whether E6n could affect the
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Fig. 1. Alignment and expression of E6, E6nI, and E6nII. (A) Alignment of the protein sequences for E6, E6nI, and E6nII. The common amino acids for these three proteins are
highlighted. (B) Expression of Flag-E6 wt, Flag-E6, and Flag-E6nI at the protein level. U2OS cells were transiently transfected with Flag-E6 wt, Flag-E6, or Flag-E6nI. Forty-
eight h post-transfection, expression was analyzed by immunoprecipitation using α-Flag agarose, followed by detection using antibodies directed against Flag-HRP. (C) and
(D) Expression of E6nI is higher than expression of E6nII in cervical cancer cell lines (C) and in U2OS cells stably transfected with pHA-E6 wt under the control of the tet
promoter (UtetE6wt) (D). qRT-PCR was performed using primers designed speciﬁcally for E6nI and E6nII. 50 primers for E6nI and E6nII were homologous to exon-exon splicing
regions, while the 50 primer for E6 was designed for intron I of E6. The 30 primer used for each of the three isoforms was homologous to the C-terminus of E6. Primers for
GAPDH were used to normalize input of cDNA. (C) The ratio between the levels of mRNA expression of E6, E6nI, and E6nII in CaSki and SiHa cells is presented as a fold-change
relative to E6 expression in CaSki cells. (D) UtetE6wt cells were grown in media without Doxycycline (Dox) (high level of E6 expression), or in media containing 100 ng/ml of
Dox (low level of E6 expression). The level of E6nI expression in UtetE6wt cells at low and high levels of Dox was set at 100%, and the level of mRNA expression of E6nII was
expressed as a percentage of E6nI expression. The lower panel of (D) shows the expression of E6 and E6n in UtetE6wt cells in the presence and absence of 100 ng/ml Dox, as
determined by immunoblot using antibodies directed against the N-terminus of E6.
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formation of tumors from both HPV16þ SiHa cells and HPV16
C33A cells. We were able to demonstrate that over-expression of
E6n in both HPV16þ SiHa cells and HPV16 C33A cells led to the
inhibition of tumor growth in nude mice, with the inhibition of
tumor growth greatest in tumors derived from HPVþ cells. These
ﬁndings suggest the involvement of both E6-speciﬁc and E6-
independent activities.
Results
E6nI is expressed at a higher level than is E6nII in both CaSki and SiHa
cells
When expressed in mammalian cells, the high-risk E6 onco-
protein is expressed as both full-length and smaller isoforms, with
the smaller isoform comprising approximately one-third of the
full-length sequence from the N-terminus of E6 (Fig. 1A, where
highlighted residues represent residues in common between E6,
E6nI, and E6nII). Because the two smaller isoforms expressed from
the E6 gene differ only in the last 7 aa of their C-terminus (Fig. 1A),
the difference in size between them is too small to be distin-
guished by immunoblot (Fig. 1B). At the RNA level, however,
3 transcripts of 0.5 kb, 0.3 kb and 0.2 kb can be detected,
which can be respectively translated into 3 proteins: the full-
length isoform of 158 aa and two smaller isoforms of 50 aa (E6nI)
and 55 aa (E6nII) (Fig. 1A). To determine which transcript corre-
sponds to the smaller protein band (Fig. 1B), we estimated the
relative levels of E6nI and E6nII expression using qRT-PCR. qRT-PCR
of E6nI and E6nII transcripts was performed using mRNA isolated
from the cervical cancer cell lines, CaSki and SiHa (Fig. 1C), as well
as from U2OStetE6 cells (Filippova et al., 2007, 2009) (Fig. 1D). In
U2OStetE6 cells, E6nI and E6nII are expressed from a stably-
transfected plasmid expressing the wild-type sequence for E6
(pE6 wt). Expression of E6 wt is under control of the tet response
element, and high and low levels of HA-E6 expression are
regulated by the concentration of doxycycline in the culture
medium (Fig. 1D bottom panel). As shown in Fig. 1C and D, the
E6nI transcript is several times more abundant than the E6nII
transcript in CaSki, SiHa, and U2OS cells, and the ratio of the levels
of the E6nI transcript to the E6n II transcript does not depend on
the level of E6 expression in U2OStetE6 cells. This data, therefore,
suggests that the smaller E6 band detected by immunoblot
(Fig. 1B) consists primarily of the E6nI transcript. The prevalence
of E6nI over E6nII expression allowed us to focus on E6nI in the
following experiments, and this gene and its corresponding
protein are henceforth referred to as E6n.
E6n expression increases levels of caspase 8, p53, and E-cadherin and
sensitizes SiHa cells to TNF
To assess the properties of E6n during tumor formation, we ﬁrst
created and characterized cervical cancer-derived cell lines
expressing E6n in the context of both an HPVþ and an HPV
background. SiHa cells stably transfected with the empty vector
pFlag are HPVþ cells with a low level of E6n expression (control),
while SiHa cells stably transfected with pE6n are HPVþ cells with a
high level of E6n. A similar pair of cell lines originating from the
HPV C33A cervical cancer cell line was also created by stably
transfecting these cells with either pFlag (C33A pFlag, control) or
pE6n (C33A E6n). After selection in G418, pE6n-expressing SiHa-
derived lines were analyzed for their level of E6n expression by
immunoblot. Eighteen clonal lines were expanded and screened,
and of these, six were selected on the basis of high levels of E6n
expression (data not shown). An equal number of cells from each
of these six lines were combined, and the resulting pooled cells
(SiHa pE6n) were used for further study. The use of pooled cells
was employed in order to minimize the possible impact of site-
speciﬁc integration events. Fig. 2A shows expression of E6n in the
pooled SiHa pE6n cells as compared to those in the pooled SiHa
pFlag cells, demonstrating increased expression levels of E6n in
cells harboring the pE6n plasmid. The relative levels of E6 and E6n
expression at the mRNA level are shown in Fig. 2B, and demon-
strate that the level of the full-length E6 transcript does not
change signiﬁcantly following over-expression of E6n. Expression
of E6n in the analogous pooled C33A-derived lines is shown in
Fig. 2C. To create these cells, 24 stable cell lines were isolated,
characterized, and equal numbers of the six C33A-derived lines
with the highest expression of E6n were pooled.
We have previously demonstrated that E6 protects U2OS cells
from TNF-induced apoptosis by decreasing the level of procaspase
8. In contrast to E6, E6n stabilizes procaspase 8, sensitizing these
cells to TNF-induced apoptosis (Filippova et al., 2007;
Tungteakkhun et al., 2008), and we found this to be true in SiHa
cells as well. Fig. 2D and E demonstrate that increasing the level of
E6n expression in SiHa cells (SiHa pE6n) leads to higher levels of
procaspase 8 as well as p53, and Fig. 2F shows that this increase in
E6n sensitizes cells to TNF. We also found that E6n expression
causes an increase in E-cadherin levels in SiHa cells, though not to
the level observed in CaSki cells (Fig. 2G). E-cadherin is a marker of
epithelial cell–cell adhesion and its function is lost in many
epithelial cancers (Hazan et al., 2004).
E6n was unable to change the level of expression of caspase 8,
p53, or E-cadherin in C33A cells (data not shown). C33A cells do
not express caspase 8 or E-cadherin, either in the absence or the
presence of E6n expression. They do express mutant p53 at high
levels (Crook et al., 1991), and over-expression of E6n did not alter
these high levels.
Expression of E6n in HPV16þ SiHa cells dramatically reduces tumor
formation in a xenograft mouse model
To determine whether expression of E6n affects tumor forma-
tion in vivo, 7.5106 cells of SiHa pFlag and of SiHa pE6n were
injected subcutaneously into each of ﬁve nude mice. SiHa pFlag
cells were injected on the left side, while SiHa pE6n cells were
injected on right side of the same mouse. Tumor formation was
assessed by measuring the tumor size approximately every 4 or
5 days with calipers. On the 88th day, mice were sacriﬁced, and
the tumor was isolated and divided into two pieces. One piece was
parafﬁn embedded, sectioned, and stained using haematoxylin-
eosin, or used for immunohistochemical detection of VEGFR-1; the
other part was used for RNA isolation.
Fig. 3A shows a representative mouse with developed tumors.
On the left side of each mouse, a large tumor derived from SiHa
pFlag cells developed, while on the right side of the same mouse,
a tumor derived from SiHa pE6n cells was in most cases barely
noticeable. The relative size of the two tumors following dissection
is shown in the bottom panel. Fig. 3B shows the relative tumor
growth for SiHa pFlag and SiHa pE6n tumors, calculated as a
percent of the tumor size on day 4 when measurements began.
During the ﬁrst 19 days following injection, the size of all tumors
decreased and remained fairly constant until day 34. SiHa pFlag
and SiHa pE6n tumors experienced a similar pattern of reduction
in size, probably due to a gradual decrease in the inﬂammation
that accompanied the initial injection of the cells. Following day
34, tumors derived from the SiHa pFlag cells began a rapid period
of growth, reaching an average volume of more than 320 mm3,
(650% of the day 4 value) by the 88th day. In contrast, tumors
derived from the SiHa pE6n cells did not grow until day 74.
Following this, a slow growth of SiHa pE6n tumors was observed,
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Fig. 2. Expression and activity of E6n in SiHa and C33A cells. (A and C) Pooled SiHa pE6n(A) and C33A pE6n (C) cells express Flag-E6n. PVDF membranes carrying the SDS-
separated proteins were probed with α-Flag-HRP antibodies, and α–β-actin antibodies were used to normalize for protein load or immunoprecipitation input, respectively
(A and C) (bottom panels). (B) The ratio between the levels of mRNA expression of E6 and E6n in SiHa pFlag and SiHa pE6n cells is presented as a fold-change relative to β-
actin expression as determined by qRT-PCR. (D, E, F) and (G) Expression of E6n in SiHa cells affects the level of expression of procaspase 8 and p53 as detected by immunoblot
(D) and by p53-ELISA (E), as well as TNF-α-induced apoptosis (F) and expression of E-cadherin (G). (D) Cell lysates prepared from SiHa pFlag and SiHa pE6n cells were treated
with 10 μMMG 132 for 16 h prior to lysis. Detection of p53 and caspase 8 was performed by immunoblot, and β-actin was used for normalization. (E) 106 SiHa pFlag or SiHa
pE6n cells were treated with either mitomycin C or DMSO (control) for 16 h prior to lysis. p53 ELISA was performed as described in Materials and methods. Data is presented
as the optical density at 405 nm per mg protein in cells treated with mitomycin C, minus that same measurement in cells not treated with mitomycin C. Measurements were
made in triplicate, and the error bars represent the standard deviation. n indicates a 0.98 level of conﬁdence. (F) 104 cells per well were seeded onto a 96-well plate. Cells
were treated with 10 μg/ml of cycloheximide in the presence or absence of 50 ng/ml of TNF-α for 16 h. Cell viability was monitored using the CellTiter-Glo Luminescent Cell
Viability Assay (Promega). nn indicates a 0.99 level of conﬁdence. (G) E-cadherin levels were detected by immunoblot in lysates prepared from SiHa pFlag, SiHa pE6n, and
CaSki cells, and normalized by β-actin.
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reaching an average volume of 67 mm3 (less than 200% of the day
4 value) by day 88 (Fig. 3B).
Over-expression of E6n in the tumors derived from the SiHa E6n
cells was demonstrated by RT-PCR (Fig. 3C). Sections from corre-
sponding tumors were pooled and used for RNA isolation. When
the Flag F and Flag R primers were used, corresponding to
sequences in the cloning vector, the product detected in the SiHa
pFlag tumors was less than 0.1 kb in size, while in the SiHa pE6n
tumors, the PCR product was greater than 0.3 kb (left and middle
panels). When primers designed for the E6 gene were used, both
the full-sized E6 and the E6n isoform were detected in both types
of tumors (right panel). However, E6n was detected at a much
higher level in tumors derived from the SiHa pE6n cells than in
tumors derived from the control cells, demonstrating that this
over-expression had not been lost during in vivo passage.
Analysis of cross-sectioned tumors stained with haematoxylin-
eosin revealed that tumors derived from SiHa pFlag and SiHa pE6n
cells differ in their morphological characteristics (Fig. 4). The large
tumors derived from SiHa pFlag cells were consistently hetero-
geneous containing sheets and nests of squamous cell carcinoma
combined with extensive leukocytic cell inﬁltration and large
areas of unstructured necrotic masses with imbedded, damaged
cells (Fig. 4A and B, left-side panels).
In contrast, the tumors derived from SiHa pE6n cells were
signiﬁcantly smaller than the SiHa pFlag tumors. These smaller
tumors were more consistently well circumscribed and encapsu-
lated, and their structure was more homogenous with the majority
of the tumor being composed of squamous cells (Fig. 4A and B,
right-side panels). One dramatic difference between the SiHa
pFlag and SiHa pE6n-derived tumors was in the size of necrotic
areas; only a small focal amount of necrosis was observed in 3 of
the 5 SiHa pE6n-derived tumors.
In addition, we employed immunohistochemistry to assess
VEGFR-1 expression in these tumor sections because the distribu-
tion and level of expression of this molecule has frequently served
as a marker of tumor angiogenesis (Harris, 2002). In tumors
derived from the SiHa pFlag cells, high levels of VEGFR-1 expres-
sion were observed in large areas of the tumor, where cells
presumably had a low oxygen supply, while areas with healthy
squamous cells exhibited low levels of VEGFR-1 (Fig. 4C, middle
panel). However, in tumors derived from the SiHa pE6n cells,
where tumors consisted primarily of healthy cells, expression of
VEGFR-1 was nearly undetectable (Fig. 4C, right panel). Only a
slight staining was observed in areas where necrotic cells were
also found.
Expression of E6n also reduces tumor formation when expressed in
HPV C33A cells
To determine whether expression of E6n would be able to
reduce tumor formation in the absence of HPV proteins, we
repeated the in vivo experiment using the HPV-negative C33A
pFlag and C33A pE6n cell lines (Fig. 2C). In this experiment, 5106
cells of C33A pFlag and C33A pE6n cells each were injected
subcutaneously into ﬁve nude mice. C33A pFlag cells were injected
on the left side, and C33A pE6n cells were injected on the right side
of the same mouse. Tumors produced by C33A cells were observed
to grow more rapidly than the tumors derived from SiHa cells. Two
mice were sacriﬁced at day 48 due to the rapid growth and
resulting size (41500 mm3) of the tumor, and the other three
mice were sacriﬁced when tumor size reached 1500 mm3. Fig. 5A
shows a representative mouse with tumors. On the left side of
each mouse a large tumor derived from C33A pFlag cells devel-
oped, while on the right side of the same mouse a smaller tumor
derived from C33A pE6n cells was formed. The relative size of the
two tumors following dissection is shown in the bottom panel of
Fig. 5A.
Fig. 5B shows the relative tumor growth for C33A pFlag and
C33A pE6n tumors, which is calculated as a percent of the tumor
size on day 7 when measurements began. In contrast to the
growth of tumors induced by SiHa-derived cells, the tumors
derived from C33A cells did not show a reduction in size at the
beginning. Tumors started to grow a week after cell injection and
gradually enlarged, with more rapid tumor growth observed
following day 45 post-injection. At day 53, the average size of tumors
derived from C33A pFlag reached 4900mm3, corresponding to more
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Fig. 3. Over-expression of E6n in SiHa cells reduces tumor growth in a tumor
xenograft model. (A) A representative mouse bearing a tumor derived from SiHa
pFlag cells on the left side and a tumor derived from SiHa E6n cells on the right side
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on the 88th day post-injection. (B) The relative average tumor volume observed for
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mean tumor volumes at day 88 were signiﬁcantly different between the two
groups (P40.99). (C) Expression of E6 and E6n at the mRNA level in dissected
tumors derived from SiHa pFlag and SiHa pE6n. Expression of Flag-E6n and Flag-E6
transcripts in tumors was detected by RT-PCR using primers speciﬁc for Flag-E6n
(Flag F and Flag R primers) (left and medium panels) and for E6 (E6-50 and E6-
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than 1200% of their size at day 7. However, tumors derived from the
C33A pE6n cells reached a size of only 273 mm3, slightly exceeding
a 400% increase (Fig. 5B).
Cross-sectioned tumors derived from C33A pFlag and C33A E6n
cells and stained with haematoxylin-eosin were characterized by
consistently heterogeneous sheets and nests of squamous cell
carcinoma combined with large areas of unstructured necrotic
masses with imbedded, damaged cells and patches of connective
tissues. Differences between C33A pFlag and C33A E6n included
larger areas of necrotic masses and connective tissues and smaller
areas of squamous cells in C33A pFlag tumors (Fig. 6A and B).
However, no signiﬁcant difference in the expression of VEGFR-1
between C33A pFlag and C33A pE6n tumors was detected by
immunohistochemistry (Fig. 6C, middle and right panels).
Reduction of tumor growth by E6n in tumors derived from HPVþ SiHa
cells is greater than in tumors derived from HPV C33A cells
A comparison of the growth curves (Figs. 3B and 5B) revealed
that the development of tumors from the SiHa and C33A cells
SiHa pFlag SiHa pE6*
Live cellsNecrotic cells
SiHa pFlag SiHa pE6*
Necrotic cells
Live cells
Negative control VEGFR-1 VEGFR-1
SiHa pFlag SiHa pFlag SiHa pE6*
Fig. 4. Sectioned SiHa tumor xenografts were stained with haematoxylin-eosin (A and B), and VEGFR-1 was detected by immunohistochemistry (C). (A) Objective 10; B
and (C) Objective 40. Arrows indicate live cells, necrotic cells, and connective tissues. (C) α-VEGFR-1 antibodies were applied to the indicated sections, while no primary
antibodies were applied to negative controls. Sections were then counter-stained with haematoxylin.
M. Filippova et al. / Virology 450-451 (2014) 153–164158
followed different dynamics. To determine how expression of
E6n impacted these dynamics in both the HPVþ SiHa and the
HPV C33A cells, the average relative sizes of E6n-expressing
tumors as a percentage of the control pFlag tumors (in the same
mouse) in SiHa and C33A cells were compared. For this compar-
ison, we selected the time period beginning when tumors were
ﬁrst detectable and ending just prior to sacriﬁce (days 40–88 post-
injection for SiHa cells, Fig. 3B; and days 17–48 post-injection for
C33A cells, Fig. 5B), during which exponential tumor growth
occurred. Fig. 7A shows the relative sizes of the E6n-expressing
tumor as compared to the corresponding control tumor during
this period. Interestingly, the trends differed between the two cell
lines. While the relative sizes of the E6n-expressing SiHa tumors
were relatively low throughout this period of exponential growth
with the ratio changing less than two-fold, the relative sizes of the
E6n-expressing C33A tumors were higher throughout the experi-
ment, and decreased more than two-fold over this time period.
One conclusion from this comparison is that the control SiHa
tumors grew signiﬁcantly faster than did the corresponding SiHa
E6n tumors, with the relative difference remaining somewhat
constant over time. In contrast, the difference between the size
of control C33A-derived tumors and those derived from the
corresponding E6n-expressing cells was smaller and increased
over time, implying increasing effectiveness of the viral protein.
In particular, the E6n-mediated reduction in size in the context of
SiHa cells ranged from 67% to 92% on day 88, (average of 79%),
while the corresponding values for the C33A cells ranged from 44%
to 72% at day 53 (average of 56%), a difference of more than 20%
(Fig. 7B). The signiﬁcance of the difference in these curves was
estimated by one-way ANOVA (P-value¼2.51107). These
results suggest that E6n may act through a different set of path-
ways in the two cell lines. In summary, E6n appears to be more
effective in suppressing tumor growth in the presence of E6 (SiHa
cells) than in its absence (C33A cells).
E6n binds to and inactivates the full-length isoform
One possible explanation for the greater reduction of tumor
size caused by E6n in SiHa as compared to C33A cells is that the
shorter isoform inhibits the oncogenic activities of the full-length
isoform. It is known, for example, that E6n proteins from both
HPV16 (Filippova et al., 2009) and 18 (Pim and Banks, 1999) can
bind to E6 and modify its activities. Fig. 7C demonstrates this
binding. In this co-immunoprecipitation experiment, U2OS cells
were co-transfected with either pFlag or pFlag-E6n together with
HA-E6. Flag-tagged proteins were precipitated using Flag-agarose,
and the co-immunoprecipitated HA-E6 was detected by immuno-
blot. The results show that HA-E6 was precipitated by Flag
antibodies from cell lysates where Flag-E6n was expressed, con-
ﬁrming the binding interaction between the proteins.
Inactivation of E6 activity by E6n has the potential to affect cell
viability and growth. To determine if this was likely to account for
the difference in tumor growth, the growth rates of both SiHa and
C33A control cells and cells expressing E6n were compared. Cells
from each line were plated and allowed to grow for 3 days, and the
number of viable cells measured every 24 h using crystal violet.
These results (Fig. 7D) demonstrate a difference in growth rate
between SiHa pE6n as compared to SiHa pFlag cells, as well as a
lack of variance in the growth rate between C33A pFlag and C33A
pE6n cells. Because the SiHa pE6n cells grow slower than SiHa
pFlag cells, an E6n-mediated reduction in growth rate could
contribute to the observed difference in SiHa-derived tumor
formation from SiHa cells, though this is unlikely to be the case
for C33A-derived tumors. Colony-forming assays also suggest that
the over-expression of E6n in SiHa cells impedes the formation of
colonies, though this trend is not apparent in C33A cells (data not
shown).
Overall, these data show that E6n can bind to the larger protein,
and that its expression reduces the growth rate of HPVþ , but not
of HPV cells. Clearly, this mechanism has the potential to
contribute to the reduction of tumor size in our HPVþ SiHa
xenograft model. However, the C33A data (Fig. 5) indicates that
additional mechanisms, which are independent of the interaction(s)
of E6n with other HPV proteins, participate as well.
Discussion
Studies over the past few decades have focused intensively on
the activities and roles of E6 proteins from high-risk types of HPV
during the process of cellular transformation, clearly implicating
E6 as a major transforming agent. However, the role of the smaller
splice isoform, E6n, in the carcinogenic process (if any) has not yet
been established. In the present study, we provide insight into the
behavior of the E6n protein during tumor growth in an in vivo
nude mouse xenograft model demonstrating that E6n displays
both E6-dependent and E6-independent anti-tumor activity. The
difference in tumor size observed in the presence and absence of
E6n, when expressed in both HPVþ (SiHa) and HPV (C33A) cells
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(Figs. 3 and 5), is dramatic and consistent, strongly indicating an
anti-oncogenic role for E6n in this context.
Opposing functions of alternatively spliced variants have previously
been demonstrated for a large number of cellular and viral genes,
including many that are associated with cancer (David and Manley,
2010; Mercatante and Kole, 2000). Alternative splicing of viral
transcripts is a well-known phenomenon, as it provides a way to
increase the encoding capacity of viral genomes, and thus to enhance
viral versatility and adaptability. Although alternatively spliced HPV
transcripts for the E6 isoforms have been known for over two decades
(reviewed in (Zheng and Baker, 2006)), an appreciation of the
opposing biological functions of the full-length and truncated isoforms
is relatively recent (Filippova et al., 2009; Guccione et al., 2004; Pim
et al., 1997). One reason for this delayed appreciation has been the
historical difﬁculty of demonstrating signiﬁcant expression of E6n at
the protein level. Indeed, it was only after the availability of appro-
priate antibodies (Euromedex, France) that our laboratory was able
to document, for the ﬁrst time, endogenous expression of E6n as a
protein in cervical cancer cells at levels comparable to that seen for
expression of the full-length isoform (Filippova et al., 2009).
Cellular models have previously been used to demonstrate
opposing functions of E6 and E6n on components of cellular
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Non-cellular
tissue
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Live cells
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Fig. 6. Sectioned C33A tumor xenografts were stained with haematoxylin-eosin (A and B), and VEGFR-1 was detected by immunohistochemistry (C). (A) Objective 10;
(B and C) Objective 40. Arrows indicate live cells, necrotic cells, and connective tissues. (C) α-VEGFR-1 antibodies were applied to the indicated sections, while no primary
antibodies were applied to negative controls. Sections were then counter-stained with haematoxylin.
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apoptotic pathways. In particular, we have reported that E6
expression protects cells from apoptosis induced by members
of the TNF superfamily (such as TNFα, FasL, and TRAIL) by
accelerating the degradation of procaspase 8. In contrast, the
binding of E6n to procaspase 8 leads to its stabilization and
increased cellular levels of the protein (Filippova et al., 2007;
Tungteakkhun et al., 2008). Consistent with these differential
effects, we found that E6 and E6n actually bind to different sites
on procaspase 8 (Tungteakkhun et al., 2010). Extending and
supporting these ﬁndings, we demonstrate here that plasmid-
expressed Flag-E6n is able to re-sensitize SiHa cells to TNFα-
induced apoptosis (Fig. 2F) through an increase in the level of
endogenous procaspase 8 (Fig. 2D). Radio-sensitization by HPV
16 E6nI has previously been reported in cells derived from
oropharyngeal squamous cell carcinoma (Pang et al., 2011),
again indicating that E6n can enhance apoptosis. Furthermore,
the negative inﬂuence of E6n on cell growth in lines transformed
both by HPV and by other mechanisms has been demonstrated
for HPV18 E6n (Pim et al., 1997), in agreement with the data
from our SiHa model (Fig. 7D). Interestingly, E6n expression can
affect functions in addition to apoptosis and cell growth. During
the transformation process, epithelial cells frequently lose their
epithelial cell–cell contacts (Takeichi, 1993). One of the epithe-
lial adhesion proteins involved is E-cadherin, which is respon-
sible for Ca2þ-dependent cell–cell adhesion (Hazan et al., 2000).
We found that expression of E6n was partially able to restore the
level of E-cadherin in SiHa cells (Fig. 2G), although not in
C33A cells.
Interestingly, E6n can sometimes mimic E6 activity in the
absence of E6. Banks and coworkers found that E6n from HPV 18
can accelerate the degradation of some PDZ-containing proteins,
including Akt, Dlg, and MAGI-1 (Guccione et al., 2004; Pim and
Banks, 1999; Pim et al., 1997, 2009). In the absence of the full-
length isoform, it may be that E6n, corresponding to the N-
terminal half of E6, can mimic E6 through self-oligomerization
and in this way down-regulate the expression levels of certain
PDZ-proteins. Together, these data indicate that E6n is not simply a
smaller version of E6, capable of carrying out only a subset of the
biological activities executed by E6, but that E6n can act indepen-
dently of full-length E6.
The in vivo studies described here deepen and expand our
understanding of E6n, and build on previous cellular data by
showing that E6n activity can reduce tumor growth in a xenograft
nude mouse model (Figs. 3 and 5). Interestingly, we found that
tumor growth inhibition by E6n is greater in tumors derived from
SiHa cells, which are HPV16-positive, than in tumors produced by
C33A, which are HPV-negative (Figs. 3B, 5B, 7A, and 7B). This
difference implies that E6n acts by interfering with the oncogenic
activity of the full-length protein as well as through one or more
HPV-independent mechanisms. Consistent with this idea, we
found that E6n does indeed bind to the full-sized isoform
(Fig. 7C) and inhibits its ability to accelerate degradation of p53
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(Fig. 2D and E). Together, the biological activities of E6n reduce the
growth rate of SiHa pE6n cells (Fig. 7D), contributing to a reduced
growth rate of E6n-expressing tumors. These ﬁndings are consis-
tent with earlier studies showing inhibition of tumor growth in a
xenograft model following expression of shRNA directed against
E6 (Bai et al., 2006). In another study, the inhibition of both E6 and
E7 expression led to reduced cell growth and invasive ability for
SiHa cells both in vitro and in vivo (Chang et al., 2010).
E6n also displays HPV-independent anti-tumor activity, as it
was able to reduce the size of tumors derived from HPV C33A
cells (Fig. 5). Interestingly, this anti-tumor activity is likely not
p53-related because C33A cells express mutant p53 (Crook et al.,
1991). In addition, we found that the over-expression of E6n in
C33A cells does not affect cellular growth, at least in vitro (Fig. 7D).
In this case, therefore, it is likely that E6n engages one or more
other mechanisms to reduce tumor growth. For example, activa-
tion of AMPK, a cellular metabolic sensor that modulates normal
and cancer cell metabolism, inhibits cervical cancer cell growth
through a decrease in FOXM1 levels. FOXM1 is a transcription
factor reported to be abnormally upregulated in human cervical
squamous cell carcinomas, and is involved in down-regulating p27
and p21 (Chan et al., 2008). Since the phenomenon of growth
inhibition through decreased levels of FOXM1 by AMPK activation
was observed in four different cervical carcinoma cell lines,
including C33A (Chan et al., 2008), we speculate that perhaps
oncogenic factors such as FOXM1 could play an important role in
the mechanisms through which E6n inhibits growth of C33A-
derived tumors in our in vivo system as well. In addition to this
possibility, we note that the deregulation of Wnt/B-catenin signal-
ing is prevalent in many cancers of epithelial origin, including
cervical cancer (Delmas et al., 2011; Kwan et al., 2013), and it may
be that expression of E6n leads to Wnt/B-catenin dysregulation.
Our future studies will focus on elucidating the mechanisms
through which E6n mediates inhibition of tumor growth in both
C33A and SiHa cells by identifying pathways affected by E6n
expression.
Epidemiological studies of actual cases of cervical cancer have
shown differential splicing in the E6/E7 region for both HPV 16
and HPV 18 (Berumen et al., 2001; De la Cruz-Hernandez et al.,
2005), and demonstrated that patterns of HPV18 E6/E7 splicing
associated with E6 variants can be related to differences in cancer
aggressiveness and prognosis for treatment. For example, cells
isolated from tumors expressing the African variant of E6, which
express relatively high levels of E6n, formed tumors in nude mice
more slowly than did cells possessing the Asian–Amerindian
variant of E6, which express relatively low levels of E6n along
with high levels of E6 (De la Cruz-Hernandez et al., 2005). In
addition, the data reported by De la Cruz-Hernandez and cow-
orkers linked E6n expression in patient samples to higher levels of
p53, which is also consistent with our data.
The role of E6n in the virus life cycle has not yet been
established. It is known, however, that splicing of the E6/E7
transcript enhances E7 expression (Zheng et al., 2004), suggesting
that the potential for alternative splicing is of functional signiﬁ-
cance. Furthermore, HPV16 E6 alternative splicing in the epithelia
depends on the level and presence of EGF, indicating that the
splicing of E6 is not a random process (Rosenberger et al.). E6nmay
work by regulating the activity of E6 (and/or other HPV proteins
such as E2), as well as cellular proteins through protein-protein
interactions within the differentiating epithelium. Such questions
await further research. In summary, we report here for the ﬁrst
time that the smaller isoform of E6, E6n, possesses anti-oncogenic
activities that can be demonstrated in vivo. Importantly, these
biological activities are distinguishable from those of E6. Future
work will focus on the signiﬁcance of these ﬁndings in the context
of human cancers, where we will explore the possibility of
mimicking or replicating the anti-oncogenic activity of E6n in such
a way as to provide therapeutic beneﬁt. Another direction for
future research will be to determine what role E6n plays in the
viral life cycle.
Materials and methods
Reagents
MG132 (Sigma-Aldrich) was dissolved in DMSO to yield a
10 mM stock, then stored at 20 1C until use. Doxycycline (Dox)
(BD Biosciences) was dissolved in PBS to a 1 mg/ml stock. α-Flag
agarose, α-Flag-HRP conjugated antibodies, and α–β-actin were
obtained from Sigma-Aldrich. α-VEGFR-1 antibodies were pur-
chased from Epitomics, α-E6 N-terminus antibodies were obtained
from Euromedex (France), α-E-cadherin was purchased from Cell
Signaling Technology, α-caspase 8 antibodies were purchased
from BD Biosciences, α-HA was obtained from Roche Applied
Science, and secondary ImmunoPure Antibody HRP conjugated
antibodies were obtained from Fisher Scientiﬁc. α-p53 p122
antibodies were puriﬁed from conditioned media obtained during
hybridoma growth.
Cell culture
U2OS cells, derived from a human osteosarcoma, as well as
SiHa, C33A, and CaSki cells, derived from cervical carcinomas,
were obtained from the ATCC. U2OS cells and their derivatives
were cultured in McCoy's 5A medium (Invitrogen), and SiHa, C33A,
and CaSki cells were maintained in MEM medum (Mediatech, Inc).
Media was supplemented to contain 10% fetal bovine serum
(Invitrogen), penicillin (100 μ/ml) and streptomycin (100 mg/ml)
(Sigma-Aldrich). Media for U2OS cells expressing E6 under the
control of the tet-responsive element (UtetE6wt and UtetE6) was
supplemented with Tet-FBS (BD Biosciences). The description and
production of stably transfected U2OS cell lines capable of expres-
sing variable amounts of HA-E6 wt, regulated by different con-
centrations of Dox present in media, has been described
previously (Filippova et al., 2004, 2005).
Plasmids, transfection, and production of stable cell lines
The plasmid pTre-E6 (BD Clontech), which expresses HA-
tagged HPV 16 E6 wild type (E6 wt) has been cloned and described
previously (Filippova et al, 2002, 2004). The plasmids pFlag-E6 wt
(pE6wt), pFlag-E6n(pE6n), and pFlag-E6 large (pE6) were obtained
by cloning E6 wt, E6nI, or E6 large, respectively, in frame with the
N-terminal Flag-tag and the C-terminal C-myc-tag into the pFlag-
myc CMV-22 vector (Sigma-Aldrich). To produce stable cell lines
expressing E6, pE6n, or the vector control, the appropriate plas-
mids were transfected into SiHa or C33A cells using the TransIt-
LT1 Transfection Reagent (MirusBio), as directed by the manufac-
turer. Forty-eight h post-transfection, G418 (500 μg/ml) was
applied to cells and antibiotic selection applied for 3 weeks.
Expression of the desired protein was assessed by immunoblot.
Cell viability and growth assays
To measure cell survival following TNF-α treatment, SiHa-
derived cells were seeded at a density of 104 cells per well on a
96-well plate and allowed to adhere overnight. TNF-α (50 ng/ml)
was applied in the presence or absence of 10 μg/ml of cyclohex-
imide (Cx), and cells were incubated for 16 h prior to measuring
cell viability by CellTiter-Glo Luminescent Cell Viability Assay
(Promega).
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To estimate cell growth, 5103 cells were seeded into four 96-
well plates and allowed to adhere overnight. The next day (day 0)
and for the 3 days following, cells were ﬁxed in 10% formaldehyde.
Staining of cells was performed using crystal violet solution
(Sigma-Aldrich). Absorbance at 570 nm was measured after dis-
solving crystal violet in 100 μl of 10% acetic acid (Fisher Scientiﬁc).
Immunoblotting and co-immunoprecipitation
For immunoblot analysis, cells (106) were lysed in 100 μl of
Laemmli lysis buffer, then lysates were sonicated and loaded onto
a SDS-PAGE gel. After protein transfer to Immobilon P membranes
(Millipore Corporation) and blocking the membrane with 1% BSA,
primary antibodies were applied in TBST containing 1% BSA. After
incubation with primary antibodies overnight at 4 1C, membranes
were washed with TBST. Secondary ImmunoPure Antibodies
(α-mouse or α-rabbit) conjugated with horseradish peroxidase
(Fisher Scientiﬁc) were applied to the membrane for 1 h, and the
detection of signals was performed using the chemiluminescent
SuperSignal West Dura or Pico Maximum Sensitivity substrate
(Fisher Scientiﬁc).
For immunoprecipitation and co-immunoprecipitations, cells
were treated with 5 or 10 μM MG132 for 16 h prior to preparation
of lysates. For co-immunoprecipitation, 107 U2OS cells were co-
transfected with pFlag or pFlag-E6n together with pHA-E6 for 48 h,
Flag-tagged proteins were precipitated using Flag-agarose, and
bound proteins were subjected to SDS-PAGE, then transferred to a
PVDF membrane and detected by immunoblot. For the SiHa- and
C33A-related experiments, 5106 pooled cells were lysed, then
the Flag-E6n proteins were precipitated using Flag-agarose. Detec-
tion of Flag-E6n was performed using α-Flag-HRP antibodies.
PCR
Total RNA from cells was isolated using TrizolR, then tissues
were homogenized in TrizolR using a Tissue Miser homogenizer
(Fisher Scientiﬁc). cDNA was synthesized using SuperScript II
reverse transcriptase (Invitrogen) according to the manufacturer's
protocols. Semi-quantitative RT-PCR was performed using 50-
GCACCAAAAGAGAACTGCAATGT-30 and 50-TGGGTTTCTCTACGTGTT-
CTTGAT-30 primers to detect both E6 isoforms (E6 primers), or
Flag-F 50-CCAAAATCAACGGGACTTTC-30 and Flag-R 50-CACAGG-
GATGCCACCCGGG-30 to detect FlagE6n transcripts.
Quantitative real-time PCR was performed to measure the
concentration of E6 isoforms using primers designed by Hafner
et al. (2008), using the Absolute QPCR SYBR Green kit according to
the manufacturer's protocol (ABgene). Concentrations of cDNAs
were normalized using GAPDH or β-actin expression.
Implantation of tumor xenografts in mice
Five-week old female Crl:CD-1-Foxn1nu nude mice were
obtained from Charles Rivers (Cambridge, MA), maintained in
pathogen-free conditions, and fed a standard irradiated chow diet
while housed within the Animal Research Facility of the Loma
Linda VA Medical Center (Loma Linda, CA). Mice were kept at
25 1C, with a 12 h light-dark schedule and free access to food and
water. All experiments were done under protocols approved by
the Institutional Animal Care and Use Committee.
Six mice were injected subcutaneously with 31 Ga. needles in
the ﬂanks bilaterally. On the left side, 7.5106 SiHa pFlag cells or
5106 C33A pFlag cells were injected; and on the right side,
7.5106 SiHa E6n cells or 5106 C33A pE6n cells were injected,
forming two tumors per mouse. Tumor formation and size were
evaluated at 4–7 day time intervals for approximately 13 weeks for
SiHa-derived tumors and for 8 weeks for C33A-derived tumors.
Tumors were measured using calipers for two perpendicular
measurements, and tumor volume was calculated according to
the formula: Width2 Length/2. In one mouse injected with SiHa-
derived cells, and in one mouse injected with C33A-derived cells,
both tumors gradually decreased until they disappeared. These
mice were excluded from the reported averages.
All mice were killed by CO2 inhalation followed by thoracot-
omy. Tumors were explanted and dissected to obtain 2 samples
from each xenograft: formalin-ﬁxed for parafﬁn-embedding for
morphological and immunohistochemical assays, and snap frozen
in liquid nitrogen for RNA isolation.
Histochemistry and immunohistochemistry
Tumor pieces ﬁxed in formalin were embedded in parafﬁn, and
sections were cut from tumors. For histochemical analysis, sec-
tions were stained with haematoxylin-eosin and analyzed under a
light microscope. Localization of VEGFR-1 was performed using
immunohistochemistry. Rabbit monoclonal antibodies (Epitomics)
speciﬁc to VEGFR-1 (N-term) were applied to tissue sections at
1:100 dilutions. Visualization of VEGFR-1 was performed using
Vestastain Elite ABC kit (Vector Laboratories). Slides were counter-
stained by haematoxylin and analyzed under a light microscope.
p53 ELISA
The procedure for performing the p53 ELISA has been pre-
viously described (Filippova and Duerksen-Hughes, 2003). The
protein concentration in the cell lysates was measured using the
Bio-Rad DC protein assay (Bio-Rad).
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